Resolution of the Neutropenia of Felty\u27s Syndrome by Longterm Administration of Recombinant Granulocyte Colony Stimulating Factor

Felty\u27s syndrome is characterized by neutropenia, splenomegaly, and recurrent infection in patients with rheumatoid arthritis. We Used recombinant granulocyte colony stimulating factor (rGCSF) in a patient with Felty\u27s syndrome and recurrent sepsis. rGCSF induced a statistically significant increase in the patient\u27s absolute neutrophil and total white blood cell counts. During 14 months of followup taking rGCSF, disseminated varicella zoster was the only infectious complication. Except mild thrombocytopenia and a transient flare of arthritis, no serious adverse effects occurred. rGCSF may be a safe and effective therapy for Felty\u27s syndrome in selected patients